Skip to Main Content
An official website of the United States government
Login Change: CDAS is now using the NIH Researcher Auth Service (RAS) to manage our existing login options. When logging into CDAS, you will be taken to RAS, where you can select your preferred login provider to access CDAS.

Survival Analysis and the Effect of Censoring for Lung Cancer

Principal Investigator

Name
Azar Shahraz

Degrees
Ph.D.

Institution
AstraZeneca

Position Title
Associate Director

Email
shahraz.azar@gmail.com

About this CDAS Project

Study
PLCO (Learn more about this study)

Project ID
PLCO-991

Initial CDAS Request Approval
Jul 22, 2022

Title
Survival Analysis and the Effect of Censoring for Lung Cancer

Summary
The aim of this project is to study the effect of censoring in survival analysis in oncology clinical trial.
We want to investigate the best parametric/semi parametric models for survival analysis and study the effect of censoring on each type.

Aims

The aim of this project is to study the effect of censoring in survival analysis in oncology clinical trial.

Collaborators

No collaborator.